| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 10,019 | 120 |
| Net (decrease) increase in cash and cash equivalents and restricted cash | -34,592 | -18,234 |
| Cash and cash equivalents at beginning of period | 62,628 | - |
| Cash and cash equivalents at end of period | 28,036 | - |
Adverum Biotechnologies, Inc. (ADVM)
Adverum Biotechnologies, Inc. (ADVM)